



Sun Pharmaceutical Industries (Europe) B.V.
Indian Format Financial Statements
FY 2016 – 2017
1 April 2016 – 31 March 2017

VALIA & TIMBADIA
CHARTERED ACCOUNTANTS

ARVIND P. VALIA
B.COM. (Hons.), F.C.A.
HITEN C. TIMBADIA
B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664/40040216
E-mail: valtim09@gmail.com
32, Trinity Chambers,
117, Bora Bazar Street, Fort,
Mumbai – 400 001.

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.

Report on the Financial Statements

We have audited the accompanying Ind AS Financial Statements of **SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.** (the "Company"), which comprise the Balance Sheet as at March 31, 2017 and the Statement of Profit and Loss (including other Comprehensive income), the statement of Cash Flows and Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Management of the Company is responsible for the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the Accounting Standards and Accounting Principles generally accepted in India. The responsibility includes the design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation and fair presentation of the financial statements, in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Management of the Company, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion these financial statements.

VALIA & TIMBADIA
CHARTERED ACCOUNTANTS

ARVIND P. VALIA
B.COM. (Hons.), F.C.A.
HITEN C. TIMBADIA
B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664/40040216
E-mail: valtim09@gmail.com
32, Trinity Chambers,
117, Bora Bazar Street, Fort,
Mumbai – 400 001.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the financial position of the Company as at 31 March, 2017, and its financial performance including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

FOR VALIA AND TIMBADIA
CHARTERED ACCOUNTANTS
(Firm Registration No. 112241W)

PLACE: MUMBAI
DATED: 10TH May, 2017

HITEN C. TIMBADIA
Partner
Membership No. 038429.

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
BALANCE SHEET AS AT MARCH 31, 2017

in Euro

	Notes	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
ASSETS				
Non-current assets				
Property, plant and equipment	1	202.041	151.862	30.192
Other intangible assets	2	280.479	54.000	-
Other non-current assets	3	9.450	1.950	1.950
Total non-current assets		491.970	207.812	32.142
Current assets				
Inventories	4	1.309.431	1.171.129	2.676.230
Financial assets				
Other investments		-	-	-
Trade receivables	5	3.423.870	2.235.583	2.498.400
Cash and cash equivalents	6	209.361	695.273	770.870
Loans	7	19.255	19.218	22.931
Other current assets	8	691.796	130.637	303.964
Total current assets		5.653.713	4.251.840	6.272.395
TOTAL ASSETS		6.145.683	4.459.652	6.304.537
EQUITY AND LIABILITIES				
Equity				
Equity share capital	9	18.000	18.000	18.000
Other equity		(1.611.983)	(1.994.228)	(2.196.952)
Total equity		(1.593.983)	(1.976.228)	(2.178.952)
Non-current liabilities				
Financial liabilities				
Borrowings	10	3.202.955	4.122.964	1.585.366
Total non-current liabilities		3.202.955	4.122.964	1.585.366
Current liabilities				
Financial liabilities				
Trade payables	11	3.851.386	1.928.776	6.397.594
Provisions	12	390.859	265.436	417.640
Other current liabilities	13	294.466	118.704	82.889
Total current liabilities		4.536.711	2.312.916	6.898.123
TOTAL EQUITY AND LIABILITIES		6.145.683	4.459.652	6.304.537
		(0)	(0)	(0)

See accompanying notes to the financial statements

In terms of our report of even date attached

For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
Partner

Prashant Savla
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2017

in Euro

	Notes	Year ended 31-mrt-17	Year ended 31-mrt-16
Revenue from operations	14	6.723.889	7.097.322
Other income	15	5.818.848	1.248.303
Total income		12.542.737	8.345.625
Expenses			
Purchases of stock-in-trade		5.110.689	3.866.955
Changes in inventories	16	(138.302)	1.505.102
Employee benefits expense	17	5.105.267	1.816.355
Finance costs	18	79.991	37.598
Depreciation and amortisation expense	1 & 2	48.009	23.983
Other expenses	19	1.954.838	892.908
Total expenses		12.160.492	8.142.901
Profit before exceptional item and tax		382.245	202.724
Profit before tax		382.245	202.724
Profit for the year		382.245	202.724
Total comprehensive loss for the year		382.245	202.724
Earnings per equity share (face value per equity shares - ` 1)		2.123,58	1.126,24
Basic (in `)			
Diluted (in `)			
See accompanying notes to the financial statements			
In terms of our report of even date attached		For and on behalf of the Board	
For Valia & Timbadia			
<i>Chartered Accountants</i>			
Hiten C Timbadia		Prashant Savla	
Partner		Director	
Date: 10th of may 2017		Date: 8th of may 2017	
Place: Mumbai, India		Place: Hoofddorp, The Netherlands	

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
STATEMENT OF CHANGES OF EQUITY FOR THE YEAR ENDED MARCH 31, 2017

	in Euro										Total		
	Share application money pending allotment	Share suspense account	Capital reserve	Securities premium reserve	Debtenture redemption reserve	Share option outstanding account	Reserve and surplus Amalgamation reserve	Capital redemption reserve	General reserve	Retained earnings (Surplus in profit and loss)		Other comprehensive income through OCI	Effective portion of cash flow hedge
Balance as at April 1, 2015										(2.196.952)		-	(2.196.952.0)
Loss for the year										202.724			202.724.0
Other comprehensive income for the year, net of income tax													-
Total comprehensive income for the year										202.724			202.724.0
Payment of dividend													-
Corporate dividend tax													-
Scheme of amalgamation													-
Transfer of capital redemption reserve													-
Transfer of debtenture redemption reserve													-
Issue of share capital													-
Buy-back of equity shares													-
Exercise of share option													-
Transfer to General Reserve													-
Share-based payments (amortisation)													-
Balance as at March 31, 2016										(1.994.228)		-	(1.994.228.0)
Loss for the year										382.245			382.245.0
Other comprehensive income for the year, net of income tax													-
Total comprehensive income for the year										382.245			382.245.0
Payment of dividend													-
Corporate dividend tax													-
Transfer to revaluation													-
Transfer of capital redemption reserve													-
Issue of share capital													-
Buy-back of equity shares													-
Exercise of share option													-
Transfer to General Reserve													-
Share-based payments (amortisation)													-
Balance as at March 31, 2017										(1.611.983)		-	(1.611.983.0)

In terms of our report of even date attached
For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
Partner

Date: 10th of may 2017
Place: Mumbai, India

Prashant Savia
Director

Date: 8th of may 2017
Place: Hoofddorp, The Netherlands

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2017

PARTICULARS	FOR THE YEAR ENDED 31.03.2017 Amount in EUR		FOR THE YEAR ENDED 31.03.2016 Amount in EUR	
A) Cash flow From Operating Activities				
Net Profit Before Tax	382.245		202.724	
<u>Adjustments for</u>				
Profit on sale of Investment			-	
Other Income (Interest and investment income)				
Interest Expenses	79.991		37.598	
Operating (Loss) / Profit before Working Capital change	462.236		240.322	
Changes in working capital				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Decrease / (Increase) in Inventory	(138.302)		1.505.102	
Decrease / (Increase) in Sundry Debtors	(1.188.287)		262.817	
Decrease / (Increase) in Loans and Advances	(37)		3.713	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
(Decrease) / Increase - Trade & Other payables	2.223.795		(4.585.207)	
Income Tax paid				
Net Cash Flows from Operating Activities		1.359.405		(2.573.253)
B) Cash Flow from Investing Activities				
Decrease / (Increase) in Non-Current Investments				
Decrease / (Increase) in Current Investments	(276.658)		(175.670)	
Interest and investment income				
Decrease / (Increase) in Other Receivables	(568.660)		173.326	
Other Non-Operating Income				
Net Cash Flows from Investing Activities		(845.318)		(2.344)
C) Cash Flow from Financing Activities				
Decrease / (Increase) in Loans and Advances				
Proceeds from issue of Equity Shares				
Interest Income				
Increase / (Decrease) in Long Term Borrowings				
Interest Expenses				
Increase / (Decrease) in Short Term Borrowings	(1.000.000)		2.500.000	
Net Cash Flows from Financing Activities		(1.000.000)		2.500.000
Net Increase / (Decrease) in Cash & Cash equivalents		(485.913)		(75.597)
Cash & Cash Equivalents at Beginning of the year	695.273		770.870	
Cash & Cash Equivalents at the End of the Year	209.361		695.273	

Note : Cash & Cash Equivalents Consist of the cash /cheque in hand & bank balance in current Account.

In terms of our report of even date attached
For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
Partner

Prashant Savla
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
 NOTES FORMING PART OF FINANCIAL STATEMENTS AS AT AND FOR YEAR ENDED MARCH 31, 2017

NOTE : 1

PROPERTY, PLANT AND EQUIPMENT

in Euro

	Vehicles	Office equipment	Furniture and fixtures	Total
At cost / deemed cost				
As at April 1, 2015	39.051	70.375	45.021	154.447
Additions	140.624	5.029	-	145.653
Disposals				-
Transfers				-
As at March 31, 2016	179.675	75.404	45.021	300.100
Additions	77.844	33.562	8.429	119.835
Disposals	(61.627)	(21.550)	(5.349)	(88.526)
Transfers				-
As at March 31, 2017	195.892	87.416	48.101	331.409
Accumulated depreciation and impairment				
As at April 1, 2015	38.129	50.023	36.102	124.255
Depreciation expense	14.455	6.676	2.852	23.983
Impairment loss				-
Disposals				-
As at March 31, 2016	52.585	56.700	38.953	148.238
Depreciation expense	34.330	9.995	3.684	48.009
Impairment loss				-
Disposals	(39.052)	(22.478)	(5.349)	(66.879)
As at March 31, 2017	47.863	44.217	37.288	129.368
Carrying value				
As at April 1, 2015	922	20.352	8.919	30.192
As at March 31, 2016	127.090	18.704	6.068	151.862
As at March 31, 2017	148.029	43.199	10.813	202.041

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
 NOTES FORMING PART OF FINANCIAL STATEMENTS AS AT AND FOR YEAR ENDED MARCH 31, 2017

NOTE : 2
 OTHER INTANGIBLE ASSETS

	Trademarks and Designs	Total
At cost / deemed cost		
As at April 1, 2015		-
Additions	54.000,0	54.000,0
Disposals		-
As at March 31, 2016	54.000,0	54.000,0
Additions	226.479,0	226.479,0
Disposals		-
As at March 31, 2017	280.479,0	280.479,0
Accumulated amortisation and impairment		
As at April 1, 2015		-
Amortisation expense		-
Disposals		-
As at March 31, 2016	-	-
Amortisation expense		-
Disposals		-
As at March 31, 2017	-	-
Carrying value		
As at April 1, 2015	-	-
As at March 31, 2016	54.000,0	54.000,0
As at March 31, 2017	280.479,0	280.479,0

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
 NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 3

OTHER NON-CURRENT ASSETS

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Advances other than capital advances			
Advance Income Tax	9.450	1.950	1.950
	9.450	1.950	1.950

NOTE : 4

INVENTORIES

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Lower of cost and net realisable value			
Stock-in-trade	1.309.431	1.171.129	2.676.230
Goods in transit	1.309.431	1.171.129	2.676.230
	1.309.431	1.171.129	2.676.230

NOTE : 5

TRADE RECEIVABLES

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Current			
Unsecured considered good	2.005.180	1.471.536	696.474
Unsecured considered good - from related parties	1.418.690	764.047	1.801.926,0
	3.423.870	2.235.583	2.498.400

NOTE : 6

CASH AND CASH EQUIVALENTS

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Cash on hand	397,0	201,0	
Balances with banks			
In current accounts	208.964	695.072	770.870
	209.361	695.273	770.870

NOTE : 7

CURRENT LOANS AND ADVANCES

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Unsecured considered good unless stated otherwise			
Amortised cost			
Loans to employees	16.199	14.662	19.818
Loans to others	3.056	4.556	3.113
	19.255	19.218	22.931

NOTE : 8

OTHER CURRENT ASSETS

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Unsecured considered good unless stated otherwise			
Prepaid expenses	51.678	128.044	87.058
Advances for supply of goods and services			203.871
Balances with government authorities	27.411	2.593	13.035
Doubtful			
Advances for supply of goods and services	612.707		
	691.796	130.637	303.964

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
 NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 9
 EQUITY SHARE CAPITAL

	As at 31-mrt-17		As at 31-mrt-16		As at 1-apr-15	
	No. of shares	in Euro	No. of shares	in Euro	No. of shares	in Euro
Authorised						
Equity shares of ` 1 each	90.000	90.000	90.000	90.000	90.000	90.000
Cumulative preference shares of ` 100 each						
	90.000	90.000	90.000	90.000	90.000	90.000
Issued, subscribed and fully paid up						
Equity Shares of ` 1 each	180	18.000	180	18.000	180	18.000
	180	18.000	180	18.000	180	18.000
Reconciliation of fully paid equity shares						
Opening balance	180,00	18.000	180,00	18.000		
Add : shares allotted during the year pursuant to the scheme of amalgamation						
Add : shares allotted to employees on exercise of employee stock option (excluding shares held by ESOP trust)						
Less : buy back of shares						
Closing balance	180,00	18.000	180,00	18.000		
Details of shareholders holding more than 5% in the Company						
Equity shares						
Alkaloida Chemical Company Zrt.	180,00	100,00				

NOTE : 10
 NON CURRENT BORROWINGS

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Unsecured			
At amortised cost	3.202.955	4.122.964	1.585.366
	3.202.955	4.122.964	1.585.366

NOTE : 11
 TRADE PAYABLES

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Trade payables to micro, small and medium enterprises	3.346.156	1.611.393	5.354.385
Trade payables to related parties	505.230	317.383	1.043.209
Others			
	3.851.386	1.928.776	6.397.594

NOTE : 12
 SHORT TERM PROVISIONS

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Employee Benefits	162.258	162.258	58.549
Product returns	228.601	103.178	359.091
	390.859	265.436	417.640

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 13
OTHER CURRENT LIABILITIES

	in Euro		
	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Statutory remittances	205.176	118.704	82.889
Advance from customers	89.290		
	294.466	118.704	82.889

NOTE : 14
REVENUE FROM OPERATIONS

	in Euro	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Sale of products (including excise duty)	6.723.889	7.097.322
	6.723.889	7.097.322

NOTE : 15
OTHER INCOME

	in Euro	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Interest income on :		
Others	-	1.334
	-	1.334
Other non-operating income (net of expenses directly attributable to such income)		
Gain on sale of financial assets measured at fair value through profit and loss, net	9.387	
Sundry balances written back, net	4.033	1.232
Miscellaneous income	5.805.428	1.245.737
	5.818.848	1.248.303

NOTE : 16
CHANGES IN INVENTORIES

	in Euro	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Inventories at the beginning of the year	1.171.129	2.676.231
Inventories at the end of the year	(1.309.431)	(1.171.129)
	(138.302)	1.505.102

NOTE : 17
EMPLOYEE BENEFITS EXPENSE

	in Euro	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Salaries and wages	4.528.248	1.497.357
Contribution to provident and other funds	399.386	219.674
Staff welfare expenses	177.633	99.324
	5.105.267	1.816.355

NOTE : 18
FINANCE COSTS

	in Euro	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Interest expense on borrowing and others	79.991	37.598
	79.991	37.598

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 19

OTHER EXPENSES

	in Euro	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Rent	174.868	161.414
Insurance	20.580	8.796
Selling and distribution	66.516	84.344
Commission and discount	243.733	
Others	44.933	11.624
Printing and stationery	13.644	9.799
Travelling and conveyance	222.798	72.100
Overseas travel and export promotion	93.463	103.386
Communication	68.947	31.449
Professional, legal and consultancy	840.572	225.850
Net (gain) / loss on foreign currency transactions and translation	10.154	28.802
Payments to auditors (net of input credit, where applicable)		
As auditors	2.000	22.750
Miscellaneous expenses	152.630	132.594
	1.954.838	892.908
Less : Receipts from Research Activities		
	1.954.838	892.908

SUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
NOTES FORMING PART OF FINANCIAL STATEMENTS AS AT AND FOR YEAR ENDED MARCH 31, 2017

NOTE : 20

(A) ACCOUNTING POLICIES :

1. Basis of Accounting

The Company has prepared financial statements for the year ended March 31, 2017 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 together with the comparative period data as at and for the year ended March 31, 2016. Further, the Company has prepared the opening balance sheet as at April 1, 2015 (the transition date) in accordance with Ind AS.

Upto the year ended March 31, 2016, the company prepared its financial statements in accordance with the requirements of previous GAAP, which includes Standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended).

The financial statements have been prepared on the historical cost basis, except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods, services, etc. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

2. Financial Assets

i. Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date.

ii. Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments and equity instruments at fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

iii. Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding

This category is the most relevant to the Group. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in Other Income in the profit or loss. The losses arising from impairment are recognised in the profit or loss.

iv. Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.

In addition, the group may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The group has not designated any debt instrument as at FVTPL.

Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the profit or loss

v. Equity instruments

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the profit or loss

3. Financial liabilities and equity instruments

Classification as debt or equity

Debt and equity instruments issued by a group entity are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument

a. Equity Instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by a group entity are recognised at the proceeds received, net of direct issue costs.

b. Compound financial instruments

The component parts of compound financial instruments (convertible notes) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument

i. Initial recognition and measurement

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

ii. Subsequent measurement

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

Financial liabilities at fair value through profit or loss

Financial liabilities are classified as at FVTPL when the financial liability is either contingent consideration recognised by the Group as an acquirer in a business combination to which Ind AS 103 applies or is held for trading or is designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred principally for the purpose of repurchasing in the near term or on initial recognition it is part of a portfolio of identified financial instruments that the Group manages together and has a recent actual pattern of short-term profit-taking. This category also includes derivative entered into by the group that are not designated and effective as hedging instruments in hedge relationships as defined by Ind AS 109. Gains or losses on liabilities held for trading are recognised in the profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For non-held-for-trading financial liabilities designated as at FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss, in which case these effects of changes in credit risk are recognised in profit or loss. These gains/ loss are not subsequently transferred to profit or loss. All other changes in fair value of such liability are recognised in the statement of profit or loss. The group has not designated any financial liability as at fair value through profit and loss.

Financial liabilities subsequently measured at amortised cost

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortised cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item

4. Recognition of Revenue

Revenue is measured at the fair value of the consideration received or receivable.

a. Rendering Services

Revenue from services rendered is recognized in the profit or loss as the underlying services are performed. Upfront non-refundable payments received are deferred and recognized as revenue over the expected period over which the related services are expected to be performed.

b. Interest Income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

c. Profit from Investments

Profit from Non Current Investments are calculated on the basis of FIFO method.

Profit from Current Investments are calculated on the basis of NAV.

5. Risk Management

The Company's activities are not exposed to any material financial risks including market risk, credit risk and liquidity risk.

5.a Accounting Standard (AS-20) on Earnings Per Share

	Year ended 31st March, 2017	Year ended 31st March, 2016
Profit for the year - used as Numerator for calculating Earnings Per Share	382.245	202.724
Weighted Average number of Shares used in computing Basic Earnings Per Share	180	180
Add: Dilution effect of Employee Stock Options	-	-
Weighted Average number of Shares used in computing Diluted Earnings Per Share	<u>180</u>	<u>180</u>
Nominal value per share (in Euro)	100	100
Basic Earnings Per Share (in Euro)	2.124	1.126
Diluted Earnings Per Share (in Euro)	2.124	1.126

5.b Related Party Transactions

	Year ended 31st March, 2017	Year ended 31st March, 2016
Sales of Goods		
Alkaloida Sweden	-	517.577
Terapia SA	-	38.400
Other Income		
Sun Pharma Global (FZE)	-	42.489
Sun Pharmaceutical Spain SLU	-	73.556
Sun Pharmaceuticals Italy SRL	-	252.719
Sun Pharmaceutical UK Ltd.	-	229.458
Sun Pharmaceuticals Germany GmbH	269.568	219.113
Sun Pharmaceuticals France	49.023	135.881
Alkaloida Sweden AB	441.060	283.504
Basics GmbH	1.561.979	-
Laboratorios SL	826.276	-
Ranbaxy Italia SpA	817.347	-
Ranbaxy Pharmacie Generiques SAS	685.540	-
Ranbaxy (UK) Ltd	1.016.837	-
Terapia SA	44.548	-
Purchase of Goods		
Sun Pharma Global (FZE)	3.767.749	3.151.443
Sun Pharmaceutical Industries Ltd	80.821	219.537
Terapia SA	189.172	192.102
Ranbaxy Laboratorios Ltd	839.869	51.285
Ranbaxy UK Ltd	8.586	1.797
Sun Pharmaceuticals France	14.580	-
Interest Expense		
Alkaloida Chemical Company Zrt.	79.991	37.598
Other Expenses		
Alkaloida Chemical Company Zrt.	211.662	67.860
Terapia SA	356.618	4.200
Trade Receivables		
Sun Pharmaceutical Industries Ltd	66.096	721.266
Sun Pharmaceutical Spain, SL.	-	44.687
Sun Pharmaceuticals Italia S.R.L.	-	152.651
Sun Pharmaceutical UK Ltd.	-	106.418
Sun Pharmaceuticals Germany GmbH	43.836	117.008
Sun Pharmaceuticals France	-	52.113
Alkaloida Sweden AB	96.818	250.469
Ranbaxy UK Ltd	-	327
Ranbaxy Italia SpA	-	26.597
Sun Pharma Global (FZE)	596.305	-
Ranbaxy Laboratorios Ltd	4.837	-
Basics GmbH	270.975	-
Laboratorios Ranbaxy S.L.	187.427	-
Ranbaxy Italia S.p.A	173.026	-
Ranbaxy Pharmacie Generiques SAS	143.348	-
Ranbaxy (U.K.) Ltd.	205.627	-
Terapia S.A.	215.433	-
Sun Pharma Laboratories Ltd. (formerly Sun Resins & Polymers Pvt Limited)	535	-
Loans Taken		
Alkaloida Chemical Company Zrt.	3.202.955	4.122.964
Trade Payable		
Alkaloida Chemical Company Zrt.	80.618	15.850
Sun Pharma Global (FZE)	2.659.704	1.472.535
Terapia SA	224.859	96.731
Ranbaxy Laboratorios Ltd	210.039	25.734

Basics GmbH	-	543
Sun Pharmaceuticals France	22.836	-
Ranbaxy Italia S.p.A	4.552	-
Ranbaxy (U.K.) Ltd.	125.447	-
Ranbaxy Ireland Ltd.	13.899	-
Ranbaxy Poland Sp Zoo	4.202	-

6. Taxes on Income

Income tax expense consists of current and deferred tax. Income tax expense is recognized in profit or loss except to the extent that it relates to items recognized in other comprehensive income or directly in equity, in which case it is recognized in other comprehensive income or directly in equity respectively. Current tax is the expected tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profits and taxable temporary differences arising upon the initial recognition of goodwill

Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the end of the reporting period.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

7. Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised only when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate of the amount of the obligation can be made. Contingent liability is disclosed for (i) Possible obligations which will be confirmed only by future events not wholly within the control of the Company or (ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made. Contingent Assets are not recognised in the financial statements.

8 Inventories

Inventories consisting of stock-in-trade are measured at the lower of cost and net realizable value. The cost of all categories of inventories is based on the weighted average method. Cost of raw stock-in-trade comprises cost of purchases. Cost of inventories also include all other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and costs necessary to make the sale.

9 Accounting policies not specifically mentioned above will be as per generally accepted accounting principles in India.

(B) First-time adoption of Ind-AS

These financial statements for the year ended March 31, 2017 have been prepared in accordance with Ind AS. For the purposes of transition to Ind AS, the Company has followed the guidance prescribed in Ind AS 101 - First Time adoption of Indian Accounting Standard, with April 1, 2015 as the transition date. The transition to Ind AS has resulted in changes in the presentation of the financial statements, disclosures in the notes thereto and accounting policies and principles. The accounting policies set out in Note A have been applied in preparing the standalone financial statements for the year ended March 31, 2017 and the comparative information.

In terms of our report of even date attached

For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
Partner

Prashant Savla
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands